Impending patent expiries, increasing competition and changes in legislation: where will generics go from 2009 onwards? Our new report - World Generics Market 2009-2024 - explains the opportunities and challenges there

The generic pharmaceuticals sector has been expanding strongly in recent years as the need for cheaper medicines worldwide has increased. The next five years from 2009 will see more leading drugs going off patent, thus increasing opportunities for generics producers. Regulations favouring generic products give cause for optimism in the generics sector, while still leaving scope for novel branded drugs. We predict that total revenues in the generics market will continue to increase in the years ahead.

Major players have been moving into the generic drugs market - spearheaded by leading pharma companies and specialist pharma organisations. Established generics companies, such as Teva, are increasing in commercial prominence and international reach. There are many rising challengers in developed and developing countries, inspired by patent expiry on major drugs. What will be the main challenges and the main opportunities in this market from 2009 onwards? Our new report, World Generics Market 2009-2024, investigates such questions in depth, providing you with the information that you need.

This report reveals forecasted sales in the world generics market and in leading national markets, providing detailed quantitative and qualitative data. In particular, World Generics Market 2009-2024 includes generics market forecasts for:

• The US
• Europe (with special focus on Germany, France, the UK, Italy and Spain)
• Japan
• China
• India
• Russia.

Our report also gives in-depth profiles of the five leading generic manufacturers: Teva, Sandoz, Mylan, Watson and Ratiopharm.

Comprehensive analysis of the global generics sector

World Generics Market 2009-2024 examines that sector critically, through a comprehensive review of information sources. This report provides detailed sales forecasts, discussions of developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 61 tables and figures and a full interview with an expert in the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy World Generics Market 2009-2024

In this report you will receive the following benefits in particular:
• You will receive an appraisal of the current world generics market
• You will receive analyses of the potential value of the world generics market, including detailed revenue forecasts from 2009 to 2024
• You will receive analyses of the most-promising areas for generic drug development and marketing
• You will receive forecasts for principal geographical markets, especially those with high growth potential
• You will examine strengths and weaknesses of the worldwide generics sector from 2009 onwards, especially commercial drivers and restraints
• You will discover expert opinion from our industry survey.

You can obtain this report today

Nobody with an interest in the generics sector can afford to overlook this new market study. The market environment in many countries will change, especially with the further rise in economic power of China and India. With an increasing focus on lowering healthcare costs, widening treatment access and patent expiries, this sector holds the potential for high, growing revenues from 2009 onwards. Do you want to know more about the rising generics market? You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6